Nicole Fawcett

A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment. 

A study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential pathway for new treatments.

As recommendations suggest extending hormone-based breast cancer treatment to 10 years for some patients, a recent study sheds light on whether patients are opting for it.

Researchers from the University of Michigan received a $6 million center grant from the National Institutes of Health to establish the new National Center for Biomedical Imaging and Bioengineering (NCBIB).

University of Michigan Health Rogel Cancer Center scientists identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an existing class of drugs, suggesting a potential treatment strategy for patients with aggressive subtypes of prostate cancer.

Susan and Richard Rogel have given $50 million to create the Rogel and Blondy Center for Pancreatic Cancer at Michigan Medicine.

Research by the University of Michigan Health Rogel Cancer Center finds that patients with three of these variants face no extra risk of dying from their cancer.

A specialist outlines some recent advances that have him excited for the future of multiple myeloma treatment.

Cuneo appointed associate director for clinical research; Magenau to serve in new assistant director role

The first large scale analysis finds immune checkpoint inhibitors are equally effective in Black and white patients, with Black patients having fewer side effects.

New research has discovered why some cancers don’t respond to immunotherapy treatment: A metabolite transporter within the tumor microenvironment blocks a key type of tumor cell death integral to immune response.

New Rogel and Blondy Center for Pancreatic Cancer will bring together researchers and clinicians to drive forward new treatments and improve outcomes

In two separate papers, U-M researchers describe how a gene alteration drives prostate cancer and a potential degrader that stops it

Researchers have developed a new model to help predict treatment response in patients with bladder cancer. 

A study finds that efforts to cap prescription drug spending are yielding significant out-of-pocket savings for these patients.